Genitourinary/Renal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D933SC00001 / NILEA Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial CancerHotte, Dr SebastienOpen to recruitmentNCT03682068
(CCTG) BL.13A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder CancerLalani, Dr Aly-KhanOpen to recruitmentNCT03768570
(CCTG) IND.234 / PC-BETS - Master ProtocolProstate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening ProtocolMukherjee, Dr SomOpen to recruitmentNCT03385655 (Master)
(CCTG) IND.234 / PC-BETS - Sub-Study IND.223A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT02905318
(CCTG) IND.234A/PC-BETS Sub-Study AA Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655 (A)
(CCTG) IND.234B/PC-BETS Sub-Study BA Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(B)
(CCTG) IND.234C/PC-BETS Sub-Study CA Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(C)
(CCTG) IND.234D/PC-BETS Sub-Study DA Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Mukherjee, Dr SomOpen to recruitmentNCT03385655(D)
(CCTG) IND.234E/PC-BETS Sub-Study EA Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA)Mukherjee, Dr SomOpen to recruitmentNCT03385655(E)
(CCTG) IND.234F/PC-BETS Sub-Study FA Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT03385655 (F)
(CCTG) IND.234G/PC-BETS Sub-Study GA Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT03385655 (G)
(CCTG) PR.20A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON)Quan, Dr KimmenOpen to recruitmentNCT03784755
(CCTG) REC.4 / EA8143A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)Hotte, Dr SebastienOpen to recruitmentNCT03055013
(JCC) Prostate HBINon-Targeted Low Dose Radiotherapy For Recurrent Prostate CancerDayes, Dr IanOpen to recruitmentNCT03196778
(JCC) The PBS StudyA randomized phase II trial investigating Stereotactic Body RadioTherapy (SBRT) for prostate boost irradiation in the treatment of high risk Prostate Cancer (PrCa)Tsakiridis, Dr TheosOpen to recruitmentNCT03380806
(Merck) MK-3475-641 / KEYNOTE 641A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Lalani, Dr Aly-KhanOpen to recruitmentNCT03834493
(Merck) MK-3475-921 / KEYNOTE 921A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA)Lalani, Dr Aly-KhanOpen to recruitmentNCT03834506
(Merck) MK-7339-010 / KEYLYNK-010Phase 3, Randomized, Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and ChemotherapyLalani, Dr Aly-KhanOpen to recruitmentNCT03834519
(Merck) MK-7902-011 / LEAP-011 / E7080A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Matching Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)Lalani, Dr Aly-KhanOpen to recruitmentNCT03898180
OCOG-2013-PETMUSEImpact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder StagingMukherjee, Dr SomOpen to recruitmentNCT02462239
OCOG-2019-CYTOSHRINK / CA209-7DRCytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney CancerLalani, Dr Aly-KhanOpen to recruitmentNCT04090710
(JGH) PCS IX / PCS 9The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.Tsakiridis, Dr TheosRecruitment on hold - COVID-19NCT02685397
(BMS) CA018005 / FRACTION-RCCA Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in
Participants with Advanced Renal Cell Carcinoma
Hotte, Dr SebastienSuspended/On holdNCT02996110
(BMS) CA209-73MA Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab Induction.Hotte, Dr SebastienSuspended/On holdNCT04088500
(UHN) WI222910 / ALPACAA Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based ChemotherapyMukherjee, Dr SomSuspended/On holdNCT03391479
Download PDF